This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Batchelor, T. Articles by Loeffler, J. S. Search for Related Content PubMed PubMed Citation Articles by Batchelor, T. Articles by Loeffler, J. S. Social Bookmarking                            What's this?

Primary CNS Lymphoma

From the Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Division of Neuro-Oncology, Department of Neurology, and Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Address reprint requests to Tracy Batchelor, MD, MPH, Yawkey 9E, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114; e-mail: tbatchelor{at}partners.org

Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased in incidence during the last three decades and occurs in both immunocompromised and immunocompetent hosts. PCNSL in immunocompetent patients is associated with unique diagnostic, prognostic, and therapeutic issues, and the management of this malignancy is different from that of other forms of extranodal NHL. Characteristic imaging features should be suggestive of the diagnosis, avoidance of corticosteroids, if possible, and early neurosurgical consultation for stereotactic biopsy. Because PCNSL may involve the brain, CSF, and eyes, diagnostic evaluation should include assessment of all of these regions as well as screening for possible occult systemic disease. Resection provides no therapeutic benefit and should be reserved for the rare patient with neurologic deterioration due to brain herniation. Whole-brain radiation therapy (WBRT) alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients older than age 60. Neurotoxicity typically is associated with significant cognitive, motor, and autonomic dysfunction, and has a negative impact on quality of life. Chemotherapy and WBRT together improve tumor response rates and survival compared with WBRT alone. Methotrexate-based multiagent chemotherapy without WBRT is associated with similar tumor response rates and survival compared with regimens that include WBRT, although controlled trials have not been performed. The risk of neurotoxicity is lower in patients treated with chemotherapy alone.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., November 18, 2009; (2009) mdp529v2. [Abstract] [Full Text] [PDF]

				L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509. [Abstract] [Full Text] [PDF]

				U. Schlegel Review: Primary CNS lymphoma Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104. [Abstract] [PDF]

				F. P. da Silva-Junior, R. d. C. Nogueira, R. Nitrini, L. T. Lucato, M. Scaff, and P. E. Marchiori Atypical Presentation of Primary Central Nervous System Lymphoma Arch Neurol, March 1, 2009; 66(3): 406 - 407. [Full Text] [PDF]

				M. Linnebank, S. Moskau, A. Jurgens, M. Simon, A. Semmler, K. Orlopp, A. Glasmacher, C. Bangard, M. Vogt-Schaden, H. Urbach, et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma Neuro-oncol, January 1, 2009; 11(1): 2 - 8. [Abstract] [Full Text] [PDF]

				K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma Neuro-oncol, January 1, 2009; 11(5): 503 - 513. [Abstract] [Full Text] [PDF]

				J.-F. Mineo, A. Scheffer, C. Karkoutly, L. Nouvel, O. Kerdraon, J. Trauet, A. Bordron, J.-P. Dessaint, M. Labalette, C. Berthou, et al. Using Human CD20-Transfected Murine Lymphomatous B Cells to Evaluate the Efficacy of Intravitreal and Intracerebral Rituximab Injections in Mice Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4738 - 4745. [Abstract] [Full Text] [PDF]

				F. M. Cady, B. P. O'Neill, M. E. Law, P. A. Decker, D. M. Kurtz, C. Giannini, A. B. Porter, P. J. Kurtin, P. B. Johnston, A. Dogan, et al. Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course J. Clin. Oncol., October 10, 2008; 26(29): 4814 - 4819. [Abstract] [Full Text] [PDF]

				D. C Gammon, M. S Bhatt, B. Patel, M. Anderson, A. Van Horn, and M. J Glantz Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 153 - 156. [Abstract] [PDF]

				Y. Shibamoto, H. Ogino, G. Suzuki, M. Takemoto, N. Araki, K. Isobe, E. Tsuchida, K. Nakamura, M. Kenjo, K. Suzuki, et al. Primary central nervous system lymphoma in Japan: Changes in clinical features, treatment, and prognosis during 1985-2004 Neuro-oncol, August 1, 2008; 10(4): 560 - 568. [Abstract] [Full Text] [PDF]

				W. Huh, J. Ho Han, C.-K. Park, and S.-H. Park Primary CNS Lymphoma Presenting With Acute Blindness and Encephalocele J. Clin. Oncol., February 1, 2008; 26(4): 678 - 679. [Full Text] [PDF]

				J Vicuna-Kojchen, S Frenkel, T Siegal, E Shalom, I Chowers, and J Pe'er Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption Br J Ophthalmol, February 1, 2008; 92(2): 231 - 235. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood, February 1, 2008; 111(3): 1085 - 1093. [Abstract] [Full Text] [PDF]

				J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF]

				M. Booman, J. Douwes, M.-C. Legdeur, J. van Baarlen, E. Schuuring, and P. Kluin From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective out-growth in two immune sanctuariesy Haematologica, June 1, 2007; 92(6): e69 - e71. [Abstract] [Full Text] [PDF]

				C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511. [Abstract] [Full Text] [PDF]

				T. S. Lawrence, J. C. Buckner, and F. F. Lang CNS Malignancies: At Last, Real Progress J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227. [Full Text] [PDF]